Aviptadil

From Wikipedia, the free encyclopedia

Template:Short description

Page Module:Message box/ambox.css has no content.Page Template:Multiple issues/styles.css has no content.

Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

aviptadil
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Trade namesRLF-100 / Zyesamiô
AHFS/Drugs.comInternational Drug Names
ATC codePage Template:Plainlist/styles.css has no content.
Identifiers
  • (2S)-4-amino-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC147H237N43O43S
Molar mass3326.83 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)C(CC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(cc1)O)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)O)NC(=O)C(Cc2ccc(cc2)O)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)O)NC(=O)C(C(C)O)NC(=O)C(Cc3ccccc3)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(Cc4cnc[nH]4)N
  • InChI=1S/C147H237N43O43S/c1-18-75(12)115(142(229)180-96(56-72(6)7)131(218)183-104(145(232)233)63-110(155)200)188-139(226)106(68-192)185-134(221)101(62-109(154)199)177-130(217)95(55-71(4)5)174-132(219)97(58-81-37-41-84(195)42-38-81)175-125(212)88(33-23-26-49-149)167-123(210)89(34-24-27-50-150)171-140(227)113(73(8)9)186-118(205)76(13)164-121(208)93(47-53-234-17)170-127(214)92(45-46-107(152)197)169-122(209)87(32-22-25-48-148)166-124(211)90(35-28-51-161-146(156)157)168-129(216)94(54-70(2)3)173-126(213)91(36-29-52-162-147(158)159)172-143(230)116(78(15)193)189-136(223)98(59-82-39-43-85(196)44-40-82)176-133(220)100(61-108(153)198)178-135(222)103(65-112(203)204)182-144(231)117(79(16)194)190-137(224)99(57-80-30-20-19-21-31-80)181-141(228)114(74(10)11)187-119(206)77(14)165-128(215)102(64-111(201)202)179-138(225)105(67-191)184-120(207)86(151)60-83-66-160-69-163-83/h19-21,30-31,37-44,66,69-79,86-106,113-117,191-196H,18,22-29,32-36,45-65,67-68,148-151H2,1-17H3,(H2,152,197)(H2,153,198)(H2,154,199)(H2,155,200)(H,160,163)(H,164,208)(H,165,215)(H,166,211)(H,167,210)(H,168,216)(H,169,209)(H,170,214)(H,171,227)(H,172,230)(H,173,213)(H,174,219)(H,175,212)(H,176,220)(H,177,217)(H,178,222)(H,179,225)(H,180,229)(H,181,228)(H,182,231)(H,183,218)(H,184,207)(H,185,221)(H,186,205)(H,187,206)(H,188,226)(H,189,223)(H,190,224)(H,201,202)(H,203,204)(H,232,233)(H4,156,157,161)(H4,158,159,162)/t75-,76-,77-,78+,79+,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,113-,114-,115-,116-,117-/m0/s1 checkY
  • Key:VBUWHHLIZKOSMS-RIWXPGAOSA-N checkY
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content. ☒NcheckY (what is this?)Page Template:Nobold/styles.css has no content.  (verify)

Aviptadil is an injectable synthetic formulation of human vasoactive intestinal peptide (VIP).[1] VIP was discovered in 1970, and has been used to treat various inflammatory conditions, such as acute respiratory distress syndrome (ARDS), asthma, and chronic obstructive pulmonary disease (COPD).

Regulatory history

ARDS in COVID-19

Studies have found that aviptadil may be beneficial for severely ill patients with COVID-19 related ARDS.[citation needed] ACTIV-3, a trial examining aviptadil acetate (Zyesami), is recruiting patients as of July 2, 2021.[2] A separate trial is examining inhaled aviptadil for patients with high risk for ARDS, is ongoing as of May 21, 2021.[3] A trial for intravenous aviptadil for the same indication concluded in February 2021.[4]

US-Israeli NeuroRx Inc partnered with Relief Therapeutics to develop aviptadil in the United States. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to aviptadil for the treatment of respiratory distress in COVID-19.[5] In September 2020, NeuroRX submitted a request for an Emergency Use Authorization to the US FDA for its use in patients in intensive care.[6]

Jan 2021: Zuventus healthcare Ltd seeks approval for aviptadil from India's drug controller for emergency use in COVID-19 treatment. Mumbai's Zuventus Healthcare Ltd. has got the nod to conduct Phase 3 clinical trials of aviptadil injectable formulation. The SEC noted that Zuventus had presented revised Phase 3 clinical trial protocol before the committee, and after "detailed deliberation", it recommended grant of permission of Phase 3 trials with the drug.[7][8]

May 2021: NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (aviptadil-acetate) and Submits Emergency Use Authorization Application to USFDA to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure.[9]

April 2022: The Central Licensing Authority, DCGI granted avipatdil manufacturing and marketing permission to Zuventus Healthcare Ltd under the brand name 'Oxyptadil', for treatment in patients with severe COVID-19 with ARDS.

Aviptadil/phentolamine combination for Erectile Dysfunction (ED)

October 2000 UK (Invicorp): aviptadil, in combination with the adrenergic drug phentolamine, is approved as an effective alternative therapy for erectile dysfunction (ED) patients. One dose intracavernosal injection contains 25 micrograms aviptadil and 2 mg of phentolamine mesilate for the treatment of ED. Aviptadil dose used for treatment of erectile dysfunction is a lot smaller than that for the treatment of ARDS.[10][11]

Vasoactive intestinal peptide (VIP)

Vasoactive intestinal peptide (VIP) is a 28-residue amino acid peptide first characterized in 1970 that was initially isolated from porcine duodenum. A member of the secretin/glucagon hormone superfamily, VIP was initially discovered owing to its potent vasodilatory effects (as its name implies). VIP is widely distributed in the central and peripheral nervous system as well as in the digestive, respiratory, reproductive, and cardiovascular systems as a neurotransmitter and neuroendocrine releasing factor. These effects contribute to an extensive range of physiological and pathological processes related to development, growth, and the control of neuronal, epithelial, and endocrine cell function.[12]

VIP receptors

VIP acts on two receptors - VPAC1 and VPAC2, which are class B of G-protein-coupled receptors (GPCRs).VPAC1 is mainly present in the lung and T-lymphocytes, whereas VPAC2 is mainly seen in the smooth muscle, mast cells and the basal parts of the lung mucosa.[13]

Expression of VIP

VIP is produced in the neurons in the central and peripheral nervous systems. VIP is mainly localized in the myenteric and submucosal neurons and nerve terminals in the GI tract. Endogenous VIP is released by numerous stimuli such as acetylcholine (ACh), ATP, serotonin (5-HT), substance P (SP), GLP-2 from at least two populations of VIP-positive nerves: cholinergic and non-cholinergic VIP-releasing nerves. In guinea pig small intestine, most VIP-positive nerves in the mucosa and submucosa are non-cholinergic secretomotor neurons and well colocalized with neuronal nitric oxide synthase (nNOS) in human colonic circular muscles. VIP is also expressed in immune cells, such as activated T cells and therefore present in lymphoid tissues including Peyer's patches, the spleen, and lymph nodes, in addition to the VIP-ergic innervation in lymphoid tissues. Beside the neuronal source, VIP is also expressed and released from endocrine organs - Heart, Thyroid, Kidney and GI tracts.[12]

Localization of VIP

  • VIP is highly localised in lungs (70%) and binds with alveolar type II (AT II) cells via VPAC1.[citation needed] The biological (vasodilator) activity of vasoactive intestinal peptide (VIP) was discovered in the lungs before the peptide was isolated and chemical identity characterized from intestine. VIP levels are also considerably high in the brain and the gut. It is localized in key sites in the lung, has potent activities on its major functions, and appears to play an important role in pulmonary physiology and disease.[14]
  • The principal localization of VIP-containing neurons in the tracheobronchial tree is in the smooth muscle layer, around submucosal mucous glands and in the walls of pulmonary and bronchial arteries. Immunoreactive VIP is also present in neuronal cell bodies forming microglia that provide a source of intrinsic innervation of pulmonary structures.[14]

Vasoactive Intestinal Peptide (VIP) and SARS-CoV-2

VIP is highly localised in lungs and binds with alveolar type II (AT II) cells via VPAC1 receptor. AT II cells constitute only 5% of pulmonary epithelium. Angiotensin Converting Enzyme 2 (ACE 2) surface receptors are present in AT II cells. AT II cells produces surfactant and plays an important role in the maintenance of type 1 epithelial cells. SARS-CoV-2 enters into AT II cells by binding to ACE 2 surface receptors with its spike protein.[15]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content.Keijzers GB (April 2001). "Aviptadil (Senatek)". Current Opinion in Investigational Drugs. 2 (4): 545–549. PMID 11566015. Archived from the original on 2010-09-02. Retrieved 2020-04-01.
  2. ^ Page Module:Citation/CS1/styles.css has no content.National Institute of Allergy and Infectious Diseases (NIAID) (2021-06-25). "A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19". International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, AIDS Clinical Trials Group.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Leuppi J (2021-05-20). "Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS: A Randomized, Placebo Controlled, Multicenter Trial". Clinicaltrials.gov.
  4. ^ Page Module:Citation/CS1/styles.css has no content.NeuroRx, Inc. (2021-02-23). "ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure". Lavin Consulting, LLC.
  5. ^ Page Module:Citation/CS1/styles.css has no content."Critically ill COVID-19 patients make quick recovery with treatment RLF-100". New York Post. 2 August 2020. Retrieved 3 August 2020.
  6. ^ Page Module:Citation/CS1/styles.css has no content.NeuroRx. "NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy". www.prnewswire.com (Press release). Retrieved 2020-09-24.
  7. ^ Page Module:Citation/CS1/styles.css has no content.Das S (2021-01-25). "Dr Reddy's, Zuventus get nod to conduct Covid-19 trials on repurposed drugs". Business Standard India.
  8. ^ Page Module:Citation/CS1/styles.css has no content."Recommendations of the SECmeeting to examine COVID-19 related proposals under accelerated approval process made in its 140thmeeting held on 18.01.2021 & 19.01.2021 at CDSCO, HQ New Delhi" (PDF). e COVID-19 SECmeeting (CDSCO). Retrieved 1 July 2021.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Pharmaceuticals, NRx. "NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to USFDA to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure". www.prnewswire.com.
  10. ^ Page Module:Citation/CS1/styles.css has no content.Keijzers GB (April 2001). "Aviptadil (Senatek)". Current Opinion in Investigational Drugs. 2 (4): 545–549. PMID 11566015.
  11. ^ Page Module:Citation/CS1/styles.css has no content."Procivni 25 micrograms/2 mg solution for injection" (PDF). 25 September 2015.
  12. ^ a b Page Module:Citation/CS1/styles.css has no content.Iwasaki M, Akiba Y, Kaunitz JD (2019). "Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system". F1000Research. 8: 1629. doi:10.12688/f1000research.18039.1. PMC 6743256. PMID 31559013.
  13. ^ Page Module:Citation/CS1/styles.css has no content.Mathioudakis A, Chatzimavridou-Grigoriadou V, Evangelopoulou E, Mathioudakis G (January 2013). "Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics". Hippokratia. 17 (1): 12–16. PMC 3738270. PMID 23935337.
  14. ^ a b Page Module:Citation/CS1/styles.css has no content.Said SI (June 1988). "Vasoactive intestinal peptide in the lung". Annals of the New York Academy of Sciences. 527 (1 Vasoactive In): 450–464. Bibcode:1988NYASA.527..450S. doi:10.1111/j.1749-6632.1988.tb26999.x. PMID 2898912. S2CID 26804295.
  15. ^ Page Module:Citation/CS1/styles.css has no content.Trougakos IP, Stamatelopoulos K, Terpos E, Tsitsilonis OE, Aivalioti E, Paraskevis D, et al. (January 2021). "Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications". Journal of Biomedical Science. 28 (1): 9. doi:10.1186/s12929-020-00703-5. PMC 7801873. PMID 33435929.
Retrieved from "https://cosmopedia.co/index.php?title=Aviptadil&oldid=5906216"